[MALAKOF] QoQ Annualized Quarter Result on 30-Sep-2021 [#3]

Stock
[MALAKOF] MALAKOFF CORPORATION BERHAD
Announcement Date
26-Nov-2021
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
30-Sep-2021 [#3]
Profit Trend
QoQ- -8.2%
YoY- 0.16%
Quarter Report
Latest QR
Upcoming QR
MALAKOF's Result
MALAKOF's Financial Summary
View:
Show?
Annualized Quarter Result
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Revenue 8,404,500 7,535,096 6,463,084 6,025,822 5,871,232 5,404,708 6,276,763 21.54%
PBT 589,578 392,724 469,567 539,946 572,752 386,728 444,599 20.76%
Tax -185,170 -113,676 -170,352 -171,217 -165,134 -91,112 -114,530 37.87%
NP 404,408 279,048 299,215 368,729 407,618 295,616 330,069 14.54%
-
NP to SH 340,052 203,524 254,547 327,117 356,356 241,776 286,581 12.11%
-
Tax Rate 31.41% 28.95% 36.28% 31.71% 28.83% 23.56% 25.76% -
Total Cost 8,000,092 7,256,048 6,163,869 5,657,093 5,463,614 5,109,092 5,946,694 21.93%
-
Net Worth 5,522,309 5,473,440 5,375,700 5,473,440 5,424,570 5,424,570 5,326,830 2.43%
Dividend
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Div 273,671 - 151,496 201,995 302,993 - 136,835 58.94%
Div Payout % 80.48% - 59.52% 61.75% 85.03% - 47.75% -
Equity
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Net Worth 5,522,309 5,473,440 5,375,700 5,473,440 5,424,570 5,424,570 5,326,830 2.43%
NOSH 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 0.00%
Ratio Analysis
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
NP Margin 4.81% 3.70% 4.63% 6.12% 6.94% 5.47% 5.26% -
ROE 6.16% 3.72% 4.74% 5.98% 6.57% 4.46% 5.38% -
Per Share
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
RPS 171.98 154.19 132.25 123.30 120.14 110.59 128.44 21.54%
EPS 6.96 4.16 5.21 6.69 7.30 4.96 5.86 12.18%
DPS 5.60 0.00 3.10 4.13 6.20 0.00 2.80 58.94%
NAPS 1.13 1.12 1.10 1.12 1.11 1.11 1.09 2.43%
Adjusted Per Share Value based on latest NOSH - 5,000,000
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
RPS 168.09 150.70 129.26 120.52 117.42 108.09 125.54 21.54%
EPS 6.80 4.07 5.09 6.54 7.13 4.84 5.73 12.12%
DPS 5.47 0.00 3.03 4.04 6.06 0.00 2.74 58.74%
NAPS 1.1045 1.0947 1.0751 1.0947 1.0849 1.0849 1.0654 2.43%
Price Multiplier on Financial Quarter End Date
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Date 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 -
Price 0.63 0.60 0.72 0.815 0.815 0.865 0.895 -
P/RPS 0.37 0.39 0.54 0.66 0.68 0.78 0.70 -34.70%
P/EPS 9.05 14.41 13.82 12.18 11.18 17.48 15.26 -29.47%
EY 11.04 6.94 7.23 8.21 8.95 5.72 6.55 41.76%
DY 8.89 0.00 4.31 5.07 7.61 0.00 3.13 100.94%
P/NAPS 0.56 0.54 0.65 0.73 0.73 0.78 0.82 -22.50%
Price Multiplier on Announcement Date
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Date 23/08/22 24/05/22 23/02/22 26/11/21 20/08/21 19/05/21 19/02/21 -
Price 0.655 0.625 0.705 0.755 0.83 0.845 0.835 -
P/RPS 0.38 0.41 0.53 0.61 0.69 0.76 0.65 -30.15%
P/EPS 9.41 15.01 13.54 11.28 11.38 17.08 14.24 -24.19%
EY 10.62 6.66 7.39 8.87 8.79 5.85 7.02 31.88%
DY 8.55 0.00 4.40 5.47 7.47 0.00 3.35 87.07%
P/NAPS 0.58 0.56 0.64 0.67 0.75 0.76 0.77 -17.25%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment